{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:01:07Z","timestamp":1785160867944,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>HLA-B*15:02<\/jats:italic> screening before carbamazepine (CBZ) prescription in Asian populations is the recommended practice to prevent CBZ-induced Stevens-Johnson syndrome (CBZ-SJS). However, a number of patients have developed CBZ-SJS even having no <jats:italic>HLA-B*15:02<\/jats:italic>. Herein, we present the case of a Thai patient who had a negative <jats:italic>HLA-B*15:02<\/jats:italic> screening result but later developed CBZ-SJS. Further HLA typing revealed <jats:italic>HLA-B*15:21<\/jats:italic>\/<jats:italic>B*13:01. HLA-B*15:21<\/jats:italic> is a member of the HLA-B75 serotype and is commonly found in Southeast Asian populations. Based on this case, we hypothesised that if all <jats:italic>HLA-B*15:02<\/jats:italic> carriers were prevented from CBZ prescription, another common HLA-B75 serotype marker would show its association with CBZ-SJS. To test this hypothesis, we pooled data from previous association studies in Asian populations, excluded all cases with <jats:italic>HLA-B*15:02<\/jats:italic>, and analysed the association significance of HLA-B75 serotype markers. A significant association was found between CBZ-SJS and <jats:italic>HLA-B*15:21<\/jats:italic> and <jats:italic>HLA-B*15:11<\/jats:italic>. We also applied an <jats:italic>in silico<\/jats:italic> analysis and found that all HLA-B75 serotype molecules shared similar capability in binding the CBZ molecule. In summary, this report provides the first evidence of a positive association between <jats:italic>HLA-B*15:21<\/jats:italic> and CBZ-SJS and the first <jats:italic>in silico<\/jats:italic> analysis of CBZ binding sites and details of the molecular behaviour of HLA-B75 molecule to explain its molecular action.<\/jats:p>","DOI":"10.1038\/srep45553","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T11:18:42Z","timestamp":1490872722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis"],"prefix":"10.1038","volume":"7","author":[{"given":"Kanoot","family":"Jaruthamsophon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varomyalin","family":"Tipmanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antida","family":"Sangiemchoey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornprot","family":"Limprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"BFsrep45553_CR1","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","volume":"149","author":"W Tangamornsuksan","year":"2013","unstructured":"Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M. & Tassaneeyakul, W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 149, 1025\u20131032 (2013).","journal-title":"JAMA Dermatol"},{"key":"BFsrep45553_CR2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen, P. et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126\u20131133 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep45553_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","volume":"51","author":"W Tassaneeyakul","year":"2010","unstructured":"Tassaneeyakul, W. et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926\u2013930 (2010).","journal-title":"Epilepsia"},{"key":"BFsrep45553_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/epi.12217","volume":"54","author":"YK Cheung","year":"2013","unstructured":"Cheung, Y. K. et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 54, 1307\u20131314 (2013).","journal-title":"Epilepsia"},{"key":"BFsrep45553_CR5","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/epi.12802","volume":"55","author":"AH Khor","year":"2014","unstructured":"Khor, A. H., Lim, K. S., Tan, C. T., Wong, S. M. & Ng, C. C. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis. Epilepsia 55, e120\u2013e124 (2014).","journal-title":"Epilepsia"},{"key":"BFsrep45553_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","volume":"5","author":"DV Nguyen","year":"2015","unstructured":"Nguyen, D. V. et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac. Allergy 5, 68\u201377 (2015).","journal-title":"Asia Pac. Allergy"},{"key":"BFsrep45553_CR7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","volume":"51","author":"N Kaniwa","year":"2010","unstructured":"Kaniwa, N. et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51, 2461\u20132465 (2010).","journal-title":"Epilepsia"},{"key":"BFsrep45553_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","volume":"97","author":"SH Kim","year":"2011","unstructured":"Kim, S. H. et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 97, 190\u2013197 (2011).","journal-title":"Epilepsy Res."},{"key":"BFsrep45553_CR9","doi-asserted-by":"publisher","first-page":"e0155907","DOI":"10.1371\/journal.pone.0155907","volume":"11","author":"K Jaruthamsophon","year":"2016","unstructured":"Jaruthamsophon, K., Sripo, T., Sukasem, C. & Limprasert, P. Comparison of a new in-house and three published HLA-B*15:02 screening methods for prevention of carbamazepine-induced severe drug reactions. PLoS One 11, e0155907 (2016).","journal-title":"PLoS One"},{"key":"BFsrep45553_CR10","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","volume":"43","author":"FF Gonzalez-Galarza","year":"2015","unstructured":"Gonzalez-Galarza, F. F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 43, D784\u2013D788 (2015).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep45553_CR11","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1107\/S0907444906027636","volume":"62","author":"G Roder","year":"2006","unstructured":"Roder, G. et al. Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype. Acta Crystallogr. D. Biol. Crystallogr. 62, 1300\u20131310 (2006).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr"},{"key":"BFsrep45553_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3389\/fgene.2014.00478","volume":"5","author":"A Puangpetch","year":"2015","unstructured":"Puangpetch, A. et al. HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Front. Genet. 5, 478 (2015).","journal-title":"Front. Genet"},{"key":"BFsrep45553_CR13","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","volume":"129","author":"CY Wei","year":"2012","unstructured":"Wei, C. Y., Chung, W. H., Huang, H. W., Chen, Y. T. & Hung, S. I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129, 1562\u20131569 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFsrep45553_CR14","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1080\/07391102.2015.1092476","volume":"34","author":"P Zhou","year":"2016","unstructured":"Zhou, P., Zhang, S., Wang, Y., Yang, C. & Huang, J. Structural modeling of HLA- B*1502\/peptide\/carbamazepine\/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis. J. Biomol. Struct. Dyn. 34, 1806\u20131817 (2016).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"BFsrep45553_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jmb.2008.05.023","volume":"380","author":"CA Smith","year":"2008","unstructured":"Smith, C. A. & Kortemme, T. Backrub-like backbone simulation recapitulates natural protein conformational variability and improves mutant side-chain prediction. J. Mol. Biol. 380, 742\u2013756 (2008).","journal-title":"J. Mol. Biol."},{"key":"BFsrep45553_CR16","doi-asserted-by":"publisher","first-page":"W349","DOI":"10.1093\/nar\/gkt381","volume":"41","author":"DWA Buchan","year":"2013","unstructured":"Buchan, D. W. A., Minneci, F., Nugent, T. C. O., Bryson, K. & Jones, D. T. Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res. 41, W349\u2013W357 (2013).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep45553_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1472-6807-9-51","volume":"9","author":"B Petersen","year":"2009","unstructured":"Petersen, B., Petersen, T. N., Andersen, P., Nielsen, M. & Lundegaard, C. A generic method for assignment of reliability scores applied to solvent accessibility predictions. BMC Struct. Biol. 9, 51 (2009).","journal-title":"BMC Struct. Biol."},{"key":"BFsrep45553_CR18","unstructured":"Case, D. A. et al. AMBER 16, University of California, San Francisco (2016)."},{"key":"BFsrep45553_CR19","doi-asserted-by":"publisher","first-page":"W665","DOI":"10.1093\/nar\/gkh381","volume":"32","author":"TJ Dolinsky","year":"2004","unstructured":"Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665\u2013W667 (2004).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep45553_CR20","doi-asserted-by":"publisher","first-page":"W522","DOI":"10.1093\/nar\/gkm276","volume":"35","author":"TJ Dolinsky","year":"2007","unstructured":"Dolinsky, T. J. et al. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 35, W522\u2013W525 (2007).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep45553_CR21","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexiblity. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep45553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep45553","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep45553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep45553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T23:28:42Z","timestamp":1671838122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep45553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,24]]}},"alternative-id":["BFsrep45553"],"URL":"https:\/\/doi.org\/10.1038\/srep45553","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]},"assertion":[{"value":"29 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45553"}}